Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 870Carcinoma, Non-Small-Cell Lung 637Prostatic Neoplasms 516Multiple Myeloma 443Neoplasms 425Leukemia, Myeloid, Acute 380Lymphoma 357Melanoma 335Leukemia 335Neoplasm Metastasis 322Lung Neoplasms 308Lymphoma, Non-Hodgkin 303Leukemia, Lymphocytic, Chronic, B-Cell 301Colorectal Neoplasms 282Ovarian Neoplasms 266Pancreatic Neoplasms 249Precursor Cell Lymphoblastic Leukemia-Lymphoma 241Recurrence 240Myelodysplastic Syndromes 233Glioblastoma 212Hodgkin Disease 201Lymphoma, Large B-Cell, Diffuse 197Lymphoma, Follicular 195Brain Neoplasms 195Carcinoma, Renal Cell 190Head and Neck Neoplasms 188Squamous Cell Carcinoma of Head and Neck 186Lymphoma, Mantle-Cell 171Sarcoma 158Fallopian Tube Neoplasms 139

Interventions

Nivolumab 2Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has results × Various Advanced Cancer × Clear all
NCT02387996 2022-11-01

A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer

Bristol-Myers Squibb

Phase 2 Completed
270 enrolled 14 charts

Various Advanced Cancer

NCT03130959 2022-08-09

CheckMate 908

Bristol-Myers Squibb

Phase 2 Completed
166 enrolled 33 charts

Various Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡